From:  Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis

Outcomes of studies included in the NMA

Trial, Author et al.
(Year)		TreatmentsMedian OS, months
(95% CI)		HR
(95% CIs)		Median PFS, months
(95% CI)		HR
(95% CIs)		ORR
(95% CI)※
IMbrave150, Finn et al. (2022)Atezolizumab + bevacizumab19.2
(17.0–23.7)		0.66
(0.52–0.85)		6.9
(5.7–8.6)		0.65
(0.53–0.81)		30
(25–35)
SOR13.4
(11.4–16.9)		4.3
(4.0–5.6)		11
(7–17)
ORIENT-32, Zheng et al. (2021)Sintilimab + bevacizumab biosimilarNR0.57
(0.43–0.75)		4.6
(4.1–5.7)		0.56
(0.46–0.70)		21
(17–25)
SOR10.4
(8.5–NR)		2.8
(2.7–3.2)		4
(2–8)
COSMIC-312, Robin et al. (2022)Atezolizumab + cabozantinib15.4
(96% CI 13.7–17.7)§		0.90
(96% CI 0.69–1.18)§		6.8
(99% CI 5.6–8.3)*		0.63
(99% CI 0.44–0.91)*		11
(8–14)§
SOR15.5
(96% CI 12.1–NR)§		4.2
(99% CI 2.8–7.0)*		4
(2–7)§
CARES-310, Shu et al. (2023)Camrelizumab + rivoceranib22.1
(19.1–27.2)		0.62
(0.49–0.80)		5.6
(5.5–6.3)		0.52
( 0.41–0.65)		25
(20–31)
SOR15.2
(13.0–18.5)		3.7
(2.8–3.7)		6
(3–10)
LEAP-002, Richard et al. (2023)LEN + rembrolizumab21.2
(19.0–23.6)		0.84
(0.71–1.00)		8.2
(6.4–8.4)		0.83
(0.71–0.98)		26
(22–31)
LEN + placebo19.0
(17.2–21.7)		8.1
(6.3–8.3)		18
(14–22)
REFLECT, Masatoshi et al. (2018)LEN13.6
(12.1–14.9)		0.92
(0.79–1.06)		7.4
(6.9–8.8)		0.66
(0.57–0.77)		19
(15–22)
SOR12.3
(10.4–13.9)		3.7
(3.6–4.6)		7
(4–9)
Return to article view

§ According to ITT population; * according to PITT population; ※ IMbrave150 were investigator assessed, others were Biomedical Isotope Research Center. NR: not reach